posted on 2023-04-04, 02:21authored byCindy Lin, Laura Garcia-Gerique, Erin E. Bonner, Jerome Mastio, Matthew Rosenwasser, Zachary Cruz, Michael Lawler, Luca Bernabei, Kar Muthumani, Qin Liu, Mortimer Poncz, Thomas Vogl, Marie Törngren, Helena Eriksson, Dan T. Vogl, Dmitry I. Gabrilovich, Yulia Nefedova
BM angiogenesis in tumor-free and MM-bearing mice treated with TQ.
Funding
HHS | NIH | National Cancer Institute (NCI)
Pennsylvania Department of Health (PA DOH)
American Association for Cancer Research (AACR)
Interdisciplinary Center of Clinical Research at the University of Münster
German Research Foundation
Active Biotech (Active Biotech AB)
History
ARTICLE ABSTRACT
We identified a novel mechanism by which myeloid cells promote myeloma progression independently of the adaptive immune system. Specifically, we discovered a novel role of S100A8/S100A9, the most abundant proteins produced by neutrophils and monocytes, in regulation of myeloma progression via promotion of the megakaryocyte expansion and angiogenesis. Tasquinimod, an inhibitor of S100A9, has potent antimyeloma effects as a single agent and in combination with lenalidomide and with proteasome inhibitors.